However, the precise mechanism by which diverse autoantibodies to GBM are induced in GN has not been determined. 
P
roduction of autoantibodies to diverse autoantigens, which are usually clustered or physically associated, is a characteristic of human autoimmune diseases (1) . It is well exemplified in anti-glomerular basement membrane (GBM) glomerulonephritis (GN) or Goodpasture's syndrome. Autoantibodies from patients with GN react with conformational B cell epitopes of diverse GBM proteins, which include the NC domain of collagen IV ␣3 chain (Col4␣3NC1), different chains of type IV collagen, collagen domains and S7 domains of type IV collagen, and other noncollagen components (2) (3) (4) (5) . In addition to their pathologic roles in tissue damage, the presence of anti-GBM autoantibody is one of the most important diagnostic indices for this disease. However, the precise mechanism by which autoantibodies to GBM are induced in GN has not been determined.
The mechanisms of the B cell tolerance and production of autoantibodies have been studied at several levels. First, several signal pathways have been revealed to participate in B cell selection/tolerance, especially in T-independent responses (6 -8) . However, those mechanisms cannot explain diversified autoantibody responses to clustered target antigens as seen in anti-GBM disease. Second, BcR transgenic mice have been a valuable tool in the study of B cell tolerance to a special autoantigen, because "autoreactive" B cells can be tracked easily (9, 10) . Those genetically manipulated animals have been instrumental in our understanding of B cell tolerance and activation. Obviously, mono-specific B cells in transgenic models may not be suitable for study on diversified autoantibody responses as seen in anti-GBM disease.
Many studies suggest that B cell tolerance in many cases is T cell dependent. It has been reported in several animal models that a pathogenic T cell epitope triggers production of diverse autoantibodies, or "B cell epitope spreading" (11) (12) (13) (14) . B cell epitope spreading also has been observed in our rat model for T cellmediated anti-GBM GN (15) . A single pathogenic T cell epitope pCol (28 -40) derived from collagen 4␣3 chain (Col4␣3) not only induces severe GN but also elicits an autoantibody response to diverse GBM antigens (16 -18) . It has been postulated that the T cells, activated by a pathogenic T cell epitope, may provide help to a population of autoreactive B cells, which present the same T cell epitope of endogenous autoantigens during B cell epitope spreading (19, 20) . However, it has been difficult to verify this hypothesis in normal animals because of lack of a model in which diverse autoreactive B cell populations can be tracked for analysis.
In this study, we identified the renal draining lymph node (RDLN) as the location for activation of autoreactive B cells after T cell-mediated glomerular damage in our anti-GBM GN model. Thus, diverse autoreactive B cell populations can be tracked and their activation can be studied at cellular and molecular levels. Our model provides a unique chance to investigate how the GBM-specific B cells are activated.
Materials and Methods

Antigen Preparation and Induction of GN
Peptides were synthesized on an automatic peptide synthesizer, AMS 422 (Gilson, Middleton, WI) using Fmoc chemistry and were purified by a reverse-phase C18 column on preparative HPLC (Water, Millford, MA). Purified peptides were analyzed by HPLC for purity and by mass spectrometry for the correct sequence. Peptides that exceeded 95% purity were dissolved in milli-Q water at 1 mM concentration and used for immunization or other investigative purposes. Sequences of synthesized peptides are listed in Table 1 .
Female Wistar Kyoto (WKY) rats were allowed to acclimate for a minimum of 3 d and were immunized in one hind footpad and at the base of the tail with a peptide (0.125 mol) emulsified in complete Freund adjuvant (CFA). Rats that were immunized with CFA alone served as controls. GN was evaluated by measurement of proteinuria/albuminuria and examination of renal histopathology (16) . Renal tissues fixed in Bouin's solution were used for hematoxylin and eosin staining (16) . Glomerular injury score was calculated as the following: [(number of crescentic glomeruli ϫ 100) ϩ (number of hypercellular glomeruli ϫ 50)] Ϭ total number of glomeruli.
Investigation of Renal Lymphatic Drainage
Rats were anesthetized with ketamine/xylazine (50/7 mg/kg). A small dorsal incision was made, and the left kidney was exposed through the incision. India ink (tissue culture grade; Sigma, St. Louis, MO) was injected into the external border of the renal cortex using a 20-gauge needle (three sites, 10 l/site). The animals were allowed to recover and were killed 3 to 12 h later. The RDLN, which was stained by the ink, was identified, and the presence of carbon particles in its cortical area was confirmed under a dissecting microscope.
Isolation of Kidney-Infiltrating Leukocytes
Renal cortex was sliced, placed in a cold DMEM that contained 10% FCS, ground against #100 mesh, and rinsed repeatedly. The passingthrough materials included intact glomeruli, fragmented tubules, and single cells. The single cells were separated by a cell constrainer (80 m) and designated as "interstitial cells." The glomeruli, which were collected from the cell constrainer, were then separated from the tubules by recombination of gravity sediment and low-speed centrifugation (200 rpm for 4 min) (15) . The purity of the glomeruli, which was determined under a microscope, was approximately 80 to 85%. The purified glomeruli were incubated further with collagenase IV at 37°C for 30 min with periodic stirring. After the incubation, glomerular fragments were eliminated by low-speed centrifugation (300 rpm for 5 min), and the single cells were collected by a higher speed centrifugation (1000 rpm for 10 min). Those cells were designated as "glomerular cells." Both interstitial cells and glomerular cells were stained for several leukocyte markers, including CD4, CD8, CD11b/c, OX33, and IgG/M, and analyzed with a flow cytometer (FACSCalibur; Becton Dickinson, San Jose, CA).
Flow Cytometry and Immunofluorescence Detection of pCol(28 -40)-Specific B Cells
FITC-pCol(28 -40) was commercially synthesized through Ahx at the amino terminus of the peptide (Biosynthesis, Lewisville, TX), dissolved in PBS at a concentration of 1 mM (1.8 mg/ml), and kept in the dark. ELISA confirmed that anti-pCol(28 -40) antibody bound to FITC-pCol (28 -40) .
The lymphocytes were adjusted to 5 ϫ 10 6 cells/ml and fixed in 0.5% (18) . mAb OX6, which reacts with RT.1Bl, was used to reduce the background. For immunofluorescence, frozen sections of lymph nodes were briefly fixed in cold acetone for 10 min and washed in cold PBS. The sections were preincubated with OX6 (10 g/ml) to prevent possible binding of pCol (28 -40) to MHC class II, followed by incubation with FITC-pCol(28 -40) and PE-OX33 at room temperature. The sections were sealed with a mounting solution and viewed with a confocal microscope.
In Vitro Antibody Production
Lymphocytes were isolated from either RDLN or inguinal lymph nodes (ILN). The cells were incubated in a serum-free medium at a cell density of 5 ϫ 10 6 cell/ml following our previously published method (17) . The supernatant of the culture was collected, and IgG concentration was determined by ELISA with a pair of anti-rat IgG antibodies using normal rat IgG as a standard (Southern Biotechnology, Birmingham, AL). The supernatant was dialyzed against 20 mM ammonium carbonate and lyophilized. The dried powder was re-dissolved in sterilized PBS (50 mM, pH 7.2) with 1 mg/ml BSA as a stabilizer, and the IgG concentration was re-measured. The IgG was kept at 4°C with 0.1% sodium azide for subsequent applications.
Detection of Antibody Activity
A previously described ELISA method was applied to detect antibodies to peptides (15) . Briefly, plates were coated with 50 l of peptide of 10 M in a carbonate buffer (pH 9.5). Serially diluted serum (100 to 800) was added to each well in duplicate. The bound rat IgG antibodies were detected with horseradish peroxidase-labeled goat anti-rat IgG (1:10,000; Southern Biotechnology) using O-phenoldiamine (0.25 mg/ml) as the substrate. The plates were read on an ELISA reader at 490 nm. A similar ELISA was used for detection of anti-GBM antibody using digested GBM proteins (15) . Direct immunofluorescence study was carried out to detect the anti-GBM antibody that bound to GBM in vivo (15) , using FITC-labeled goat anti-rat IgG or IgM antibodies (1:50; Southern Biotechnology). Indirect immunofluorescence was used to detect antibodies to native GBM. Rat kidney contains a significant amount of Ig, which will also be stained by anti-rat IgG. Such background is not acceptable in the case for detection of a small quantity of rat antibody to GBM. To minimize the background, we used normal human kidneys, as we have demonstrated that anti-GBM antibodies in our model also reacted with human GBM (16) . Briefly, frozen sections of normal human kidney were incubated with the testing antibody for 2 h at 20°C and washed extensively. The section was incubated further with FITC-labeled goat anti-rat IgG or IgM antibodies (1:50; Southern Biotechnology) and viewed with a confocal microscope in a doubleblind manner (FV 500; Olympus, Melville, NY). Confocal images were digitally recorded.
Purification of B Cell Population
Lymphocytes were isolated from different lymph nodes and adjusted to 10 7 cells/ml. B cells were purified with positive magnetic beads sorting following the manufacturer's instructions (MACS; Miltenyi Biotech Inc., Auburn, CA). Briefly, after preincubation with normal mouse IgG, the lymphocytes were incubated on ice with magnetic beads coated with mAb OX33 for 30 min and then added to the isolation column located in a magnetic field. The column was washed thoroughly with cold PBS, and B cells were eluted from the reverse direction in the absence of a magnetic field. The cell fractions were analyzed with flow cytometry after staining with PE-labeled OX33 and FITC-labeled anti-rat IgG/M. The purified B cells were used immediately for isolation of total RNA.
Reverse Transcription-PCR Detection of B LymphocyteInduced Maturation Protein Expression
Total RNA was isolated from lymph nodes or cell fractions at designated time points (Ambion, Austin, TX), and cDNA was synthesized using 0.1 g of total RNA through a reverse transcription (RT) reaction (RNA PCR Core Kit; Applied Biosystems, Foster City, CA). PCR was used to detect B lymphocyte-induced maturation protein (blimp) mRNA using a pair of primers (5Ј-CCTTGCTACATGTGTGTCAGTTGG-3Ј, 5Ј-TGCTAG-CATGTGTGGAATCTCTGG-3Ј), which resulted in a 400-bp product, under the following conditions: Preheating at 94°C for 3 min followed by 30 cycles (94°C for 60 s, 64°C for 30 s, 72°C for 60 s; GeneAmp9700; Applied Biosystems) (21) . Expression of a housekeeper gene (glyceraldehyde-3-phosphate dehydrogenase) was used as an internal control following a previous published RT-PCR method, which resulted in a 238-bp product (22) . The products were separated by electrophoresis in 1.5% agarose gel, stained with ethidium bromide, and visualized under ultraviolet light illumination. Selected samples were also used for real-time PCR following the identical conditions as described above. Briefly, after the RT reaction, cDNA concentrations were determined by a Microplate Spectrophotometer (SPECTRAmax; Molecular Devices, Sunnyvale, CA). Real-time PCR was carried out at two concentrations of the cDNA (1.5 ng/50 l and 0.75 ng/50 l) in duplicate in an iCycler iQ real-Time PCR detection system using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA). Housekeeper gene glyceraldehyde-3-phosphate dehydrogenase was used as the standard. Relative abundance of blimp-1 expression was calculated following the 2 Ϫ⌬⌬C T method (23) .
Results
Expansion of T and B Cells in RDLN of Rats with Anti-GBM GN
As the first step to investigate how anti-GBM antibodies were produced, we searched for the location of anti-GBM antibody production in the immunized WKY rats. Several previous studies have demonstrated the presence of B cells/extra-lymph node germinal center in the kidneys of several types of GN (24, 25) . We first examined the kidney-infiltrating leukocytes in pCol(28 -40)-immunized WKY rats. The infiltrating leukocytes were isolated from either the interstitial tissue or glomeruli of diseased kidneys at two different stages (days 25 and 40 after immunization) and analyzed by flow cytometry (Figure 1 Figure 1B) . Thus, the kidney was an unlikely location for anti-GBM antibody production. We observed that a special lymph node in close proximity to the renal hilum, above the renal vein, of each diseased kidney was consistently enlarged in the immunized WKY rats after 25 to 35 d after immunization ( Figure 2C ). However, enlargement of the lymph nodes at the same location was not observed in CFAimmunized WKY controls ( Figure 2B ). In rats that were immunized with pCol34A, which has altered specificity of T cell epitope and nonpathogenic (see Table 1 ), enlargement of the lymph node was also not observed. Thus, enlargement of the lymph node was associated only with glomerular injury as well as anti-GBM antibody.
Using India ink as a tracer, lymphatic drainage of the renal cortex was investigated. It took 3 h for the ink to stain the first lymph node, which was in the identical location of the enlarged lymph node (Figure 2A) . Microscopic observation showed accumulation of carbon particles in the cortex of the lymph node. Thus, the enlarged lymph node described above was the draining lymph node to the renal cortex. This lymph node was designated as RDLN. Quantitative analyses on the lymphocyte numbers from RDLN ranged from 31.5 up to 55 ϫ 10 6 lymphocytes/node in pCol(28 -40)-immunized WKY rats sampled at 35 to 40 d, as 
B Cells in RDLN Produce Anti-GBM
We next asked whether B cells in enlarged RDLN of diseased kidneys were specific to GBM antigens. Lymphocytes were isolated from RDLN of WKY rats 35 d after immunization with pCol(28 -40) for in vitro antibody production ( Table 2) . As an internal control, the cells that were isolated from ILN, to which the injected pCol(28 -40) drained, were used. Lymphocytes that were isolated from RDLN or ILN of the rats that were immunized with pCol34A were used as additional controls. The lymphocytes from ILN of rats that were immunized with pCol(28 -40) produced a significant amount of IgG (Table 2) . ELISA demonstrated that the produced IgG showed strong antibody activity to pCol(28 -40) ( Table 2) . However, the IgG that was produced by ILN cells, even when concentrated up to 50 g/ml, failed to react with GBM by either ELISA or immunofluorescence ( Figure 3A) .
Conversely, the lymphocytes that were isolated from RDLN of only pCol(28 -40)-immunized WKY rats produced a significant quantity of IgG ( Table 2 ). The IgG that was produced by RDLN of pCol(28 -40)-immunized WKY failed to react with pCol(28 -40) as measured by ELISA (Table 2) . However, indirect immunofluorescence demonstrated that the IgG that was produced by RDLN strongly reacted with native GBM at a concentration as low as 1 g IgG/ml ( Figure 3B ). The IgG that was produced by RDLN also showed an unanticipated reactivity with nuclear antigens, suggesting the production of anti-nuclear antibodies in RDLN as well ( Figure 3B ). In contrast, only a trace amount of IgG was detected in RDLN from pCol34A-immunized WKY rats (Table 2) . We concluded that RDLN of pCol(28 -40)-immunized WKY rats was the location of autoreactive B cells that were specific to GBM antigens. IgM antibody to GBM was undetectable by indirect immunofluorescence or ELISA. Although anti-nuclear antibody was produced by RDLN B cells, circulating anti-nuclear antibody was not detected by indirect immunofluorescence.
Absence of pCol(28 -40)-Specific B Cells in RDLN
To exclude any possible connections between GBM-and pCol(28 -40)-specific B cells, we next analyzed the specificity of B cells in both the RDLN and ILN of pCol(28 -40)-immunized WKY rats at day 20, when anti-GBM antibodies became detectable by ϩ B cells ( Figure   4A ). We also observed a population of OX33 Ϫ pCol(28 -40) ϩ , which probably was anti-GBM plasma cells, which lost CD45R expression (26) . Binding of FITC-pCol (28 -40) to the B cells was specific, as nonlabeled pCol(28 -40) could inhibit the binding. In contrast, only 0.1% of cells from RDLN of the same animals were stained as "positive" at day 20, and thus only Ͻ0.5% of B cells might be pCol (28 -40) ϩ cells ( Figure 4B ). This percentage was close to the background, which was set by lymphocytes from ILN of control rats that were immunized with CFA alone or from normal WKY. B cells that were specific to pCol(28 -40) were present in RDLN at a much later stage (day 35; 6.8%). A slightly higher percentage of pCol(28 -40)-specific B cells (7.5%) were also observed in other lymph nodes, such as axillary nodes, which were more distant from ILN. Those results suggested that presence of pCol(28 -40)-specific B cells in RDLN at a later stage probably was due to secondary migration of antigen-specific B cells throughout the lymphatic system. We concluded that pCol ( 
Timing for Activation of B Cells in RDLN
To estimate when the B cells, specific to either pCol(28 -40) or native GBM in ILN or RDLN, were activated, we established a time course of antibody response, as well as of glomerular injury, in pCol(28 -40)-immunized WKY rats ( Figure 5 ). Prominent glomerular injury was histologically observed at day 20 after immunization and rapidly developed into crescentic lesions/tuft necrosis in 100% of glomeruli after day 30 ( Figure 5A ). However, our previous study showed that significant proteinuria developed in the immunized rats at approximately 15 to 18 d, suggesting the occurrence of subhistologic damage in the GBM (16) .
IgG-type circulating antibodies to the peptide pCol(28 -40) became detectable as early as day 8, and its titer elevated rapidly after day 12. The circulating antibodies reached a plateau at day 20 and persisted at this level during the entire experimental period ( Figure 5B ). However, direct immunofluorescence showed a positive GBM-bound IgG antibody in 37% of the rats at day 20. At day 25, most (75%) of rats showed positive in the binding of antibody to GBM. After day 30, the binding of antibody to GBM became extremely intensive in most of the rats ( Figure 5C ). IgG circulating antibodies to GBM, however, were not detectable by either ELISA or indirect immunofluorescence ( Figure 5B ). On the basis of the comparisons between antibodies and glomerular damage, we concluded that production of anti-pCol(28 -40) antibodies significantly preceded the glomerular injury, but production of anti-GBM antibodies occurred after the glomerular injury. Thus, there was a significant time gap between production of anti-pCol (28 -40) antibodies in ILN and anti-GBM antibodies in RDLN. Those data also suggested that that T cell-mediated glomerular damage was a prerequisite for production of anti-GBM antibodies in the immunized rats.
For confirming the time gap between B cell activation in the two lymph nodes, expression of blimp-1, which is associated with B cell 
Discussion
Presence of anti-GBM antibody is the hallmark of Goodpasture's syndrome, or anti-GBM GN. The precise mechanism by which autoantibodies to diverse GBM antigens are produced remains unclear. We have established a rat model for anti-GBM GN in which the nephritogenic T cell epitope pCol (28 -40) , derived from Goodpasture's antigen collagen IV ␣3 chain, not only induces glomerular injury but also can elicit anti-GBM autoantibodies (15) . Our studies strongly argue that B cell epitope spreading probably occurs during glomerular damage, which leads to GBM antibody production. In this study, we further identified RDLN as the location of the autoreactive B cell activation. Thus, diverse GBM-specific B cell populations can be tracked and studied. This unique feature will greatly facilitate our investigations on the precise mechanism of GBM antibody production. We believe that our investigation will also contribute to our understanding of the mechanism of GBM antibody production as well as B cell epitope spreading.
Activation of GBM-Specific Autoreactive B Cells in RDLN
The most significant finding in this study is identification of RDLN as the specific location where the autoreactive B cells to GBM and nuclear antigens are activated. The most direct evidence came from in vitro antibody production experiments. IgG that was produced only by RDLN B cells showed strong antibody activity to native GBM. Indirect evidence also supported our conclusion. T cell epitope pCol(28 -40) also contains a peptide-specific B cell epitope (16) ( Table 1) . Because antibodies to this B cell epitope do not react with native GBM, this peptide-specific B cell epitope has served as an excellent internal control, which has allowed us to observe simultaneously activation of two B cell populations with different specificities. Using synthetic FITC-pCol(28 -40), we were able to detect or locate quantitatively pCol(28 -40)-specific B cell populations. We first demonstrated, at either day 20 or day 35, the presence of a large percentage of pCol(28 -40)-specific B cells in the ILN, to which immunized pCol(28 -40) drained. In contrast, pCol(28 -40)-specific B cells were not present in RDLN at an earlier stage (day 20), when anti-GBM antibodies had become detectable. Therefore, the expanding B cell populations in RDLN and ILN were different in their specificity: Those in ILN were pCol(28 -40) specific, whereas those in RDLN were not. Although we still lack a method to detect directly GBM-specific B cells, we are able to conclude that expanding B cells in RDLN were GBM or nuclear antigen specific. A small percentage of pCol(28 -40)-specific B cells was observed in RDLN at a later stage (day 35). Because a similar percentage of peptide-specific B cells were also seen in distant lymph nodes such as the axillary node, it is reasonable to conclude that this B cell population is not specifically expanded in RDLN but probably is a result of the secondary migration of B cells throughout the lymphatic system.
Our time-course study showed that production of anti-GBM antibodies occurred after T cell-mediated glomerular injury. In contrast, production of antibodies to pCol(28 -40) preceded glomerular injury. By tracking B cells in RDLN, we were able to determine more precisely when the GBM-specific B cells were activated. Blimp-1 is a transcription factor that is involved in differentiation of plasma cells (21) . Delayed expression of blimp in B cells from RDLN also indicates that GBM-specific B cells were activated after glomerular injury. Those results suggest that glomerular injury may be a prerequisite for activation of GBMspecific B cells.
Our Model Is a Unique Tool for Studying B Cell Epitope Spreading
Production of autoantibodies is characteristic of autoimmune diseases mediated by either an antibody or a T cell mechanism. It has been a hot topic in immunology to understand mechanisms by which autoreactive B cells are activated. Sophisticated BcR transgenic models have been instructive in our understanding of the mechanism of B cell tolerance, especially in T independent responses. However, mono-specific B cell populations limit their value for studying the mechanism of a diversified autoantibody response, which is more frequently seen among human autoimmune diseases (1) . How to track diverse B cell populations is a key to determining how autoreactive B cells are activated especially in T cell-mediated autoimmune diseases.
Our model provides an excellent tool to address this issue. First, our model for anti-GBM disease is a typical autoimmune disease model with production of anti-GBM antibody. Second, identification of the location of autoreactive B cell activation, i.e., RDLN, will allow us to study the activation of autoreactive B cells after T cell-mediated tissue damage at cellular and molecular levels without genetic manipulation. Third, a unique peptide-specific B cell epitope in pCol(28 -40) is an excellent internal control. It allows us to compare the B cell response to an immunizing "foreign" B cell epitope versus autoantigens released from T cell-mediated tissue injury. Fourth, we recently found that Lewis rats possess identical MHC to WKY. Although Lewis rats are able to mount an identical T cell response to pCol(28 -40), they do not develop anti-GBM disease or anti-GBM antibodies. Thus, Lewis rats will provide an essential control for our investigation on the factors beyond the T cell mechanism that determines B cell epitope spreading. Finally, many models for glomerular injury are mediated by mechanisms other than autoimmunity (27) (28) (29) . Those models will help us to answer why only autoreactive T cell-mediated glomerular injury leads to activation of autoreactive B cells.
Hypothesis: How Antibodies to Diverse GBM Antigens Are Produced
It has been well demonstrated that GBM patients usually produce autoantibodies to multiple GBM epitopes or proteins. On the basis of our findings in both this and previous articles, we are able to propose a general hypothetical mechanism by which diverse GBM antibodies are produced in our model ( Figure 7 ) (30) . First, a single pathogenic T cell epitope activates T cells, which cause glomerular inflammation and GBM damage. Second, damage of GBM not only leads to proteinuria but also results in release of GBM antigens, which drain to RDLN. Finally, B cells specific to GBM antigens are activated in RDLN and begin to produce diverse GBM antibodies, which eventually bind to native GBM. Thus, a single T cell epitope triggers a full clinical spectrum of anti-GBM glomerulonephritis: Proteinuria, glomerular damage, and diverse GBM antibodies. Figure 7 . Schematic diagram describes the hypothetic mechanism by which antibodies to diverse GBM antigens are produced after immunization with a single nephritogenic T cell epitope in our model. Bold arrows indicate the steps that are based on the findings described in this article.
